Cory Kasimov

Work Rating Distribution Performance Price Targets & Ratings Chart

Analyst Cory Kasimov works at JPMORGAN and is focused on the Healthcare sector with 337 price targets and ratings documented since 2012 spanning on 22 stocks. Analyst's average stock valuation to be materialised ratio is 69.19% with an average time for price targets to be met of 266.82 days.

Most recent stock forecast was given on NVCR, NovoCure Limited at 17-Mar-2023.

Cory Kasimov best performing recommendations are on EDIT (EDITAS MEDICINE, INC).
The best stock recommendation documented was for CLVS (CLOVIS ONCOLOGY, INC) at 10/31/2018. The price target of $16 was fulfilled within 7 days with a profit of $4.37 (37.58%) receiving and performance score of 53.68.

Average potential price target upside

ACAD ALKS BLUE BMRN BNTX CLVS GILD INCY MRNA NVCR PBYI RARE SANA VRTX SAGE AMGN CERE EDIT GBT KRTX REGN BIIB

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average time for PT to be met

Performance score

Buy

28

$9.5 (51.35%)

25

9 days ago

3/9 (33.33%)

$10.29 (42.30%)

168

Buy

33

$14.5 (78.38%)

26

9 days ago

25/36 (69.44%)

$11.75 (41.85%)

593

Hold

20

$1.5 (8.11%)

19

9 days ago

10/21 (47.62%)

$6.16 (21.85%)

34

Buy

26

$7.5 (40.54%)

20

9 days ago

10/16 (62.5%)

$7.71 (27.86%)

93

Buy

27

$8.5 (45.95%)

27

9 days ago

2/16 (12.5%)

$9.79 (42.07%)

71

Show more analysts
ACAD ALKS BLUE BMRN BNTX CLVS GILD INCY MRNA NVCR PBYI RARE SANA VRTX SAGE AMGN CERE EDIT GBT KRTX REGN BIIB